Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1916 1
1952 1
1955 3
1956 2
1959 2
1961 2
1965 2
1966 1
1967 3
1968 6
1969 3
1970 1
1971 1
1972 5
1973 2
1975 1
1976 4
1977 1
1978 1
1980 1
1982 1
1983 3
1984 2
1985 2
1989 2
1990 4
1991 1
1992 4
1993 6
1994 4
1995 9
1996 6
1997 3
1998 2
1999 2
2000 3
2001 5
2002 8
2003 12
2004 16
2005 10
2006 14
2007 15
2008 19
2009 26
2010 27
2011 20
2012 17
2013 11
2014 23
2015 22
2016 20
2017 11
2018 12
2019 18
2020 15
2021 15
2022 11
2023 14
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

430 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Modeling Patient-Derived Glioblastoma with Cerebral Organoids.
Linkous A, Balamatsias D, Snuderl M, Edwards L, Miyaguchi K, Milner T, Reich B, Cohen-Gould L, Storaska A, Nakayama Y, Schenkein E, Singhania R, Cirigliano S, Magdeldin T, Lin Y, Nanjangud G, Chadalavada K, Pisapia D, Liston C, Fine HA. Linkous A, et al. Among authors: fine ha. Cell Rep. 2019 Mar 19;26(12):3203-3211.e5. doi: 10.1016/j.celrep.2019.02.063. Cell Rep. 2019. PMID: 30893594 Free PMC article.
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling.
Jeon HM, Kim JY, Cho HJ, Lee WJ, Nguyen D, Kim SS, Oh YT, Kim HJ, Jung CW, Pinero G, Joshi T, Hambardzumyan D, Sakaguchi T, Hubert CG, McIntyre TM, Fine HA, Gladson CL, Wang B, Purow BW, Park JB, Park MJ, Nam DH, Lee J. Jeon HM, et al. Among authors: fine ha. Cancer Cell. 2023 Aug 14;41(8):1480-1497.e9. doi: 10.1016/j.ccell.2023.06.007. Epub 2023 Jul 13. Cancer Cell. 2023. PMID: 37451272 Free article.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Pachychoroid Disease.
Freund KB, Fine HF. Freund KB, et al. Among authors: fine hf. Ophthalmic Surg Lasers Imaging Retina. 2020 Apr 1;51(4):206-209. doi: 10.3928/23258160-20200326-01. Ophthalmic Surg Lasers Imaging Retina. 2020. PMID: 32348536 Review. No abstract available.
Reply.
Bonnell AC, Mantopoulos D, Fine HF, Shah SP, Wheatley HM, Prenner JL. Bonnell AC, et al. Among authors: fine hf. Retina. 2021 Sep 1;41(9):e67-e68. doi: 10.1097/IAE.0000000000003246. Retina. 2021. PMID: 34190724 No abstract available.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
430 results